

the group consisting of a fibroblast, a macrophage, a B cell, and a dendritic cell.

44. (Added) The method according to any of claims 26 or 39-40, wherein said tumor is a solid tumor or a hematological tumor.

45. (Added) The method of claim 44, wherein said tumor is selected from the group consisting of melanoma, lymphoma, plasmacytoma, sarcoma, glioma, thymoma, leukemias, breast cancer, prostate cancer, colon cancer, esophageal cancer, brain cancer, lung cancer, ovary cancer, cervical cancer and hepatoma.

46. (Added) The method according to any of claims 26 or 39-40, wherein said animal is a human subject.


REMARKS

Applicant respectfully submits that the foregoing amendments do not introduce new matter. More specifically, Applicant has canceled claims 1-2, 5-15, 17-25 and 27-28 without prejudice. Claims 16 which, as originally filed, depends from claims 1-4 and 9-10, has been amended to incorporate the delineations of claim 1. Claim 26 which, as originally filed, depends from claims 2-4, has been amended to incorporate the delineations of claim 2. Added claims 29-32 are supported by claim 16 as originally filed. Added claims 33-35 and 37 are

supported by claims 17-20 as originally filed. Support for added claim 36 is found in the present specification, e.g., at page 8. Support for added claim 38 is found in the present specification, e.g., at page 35. Added claims 39-40 are supported by claim 26 as originally filed. Added claims 41-45 are supported by claim 26 as originally filed and by the specification, e.g., at pages 35-37. Support for added claim 46 is found in the present specification, e.g., at page 35..

It is respectfully submitted that the present case is in condition for allowance, which action is earnestly solicited.

Respectfully submitted,


Leopold Presser
Registration No. 19,827

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343
FSD/LP/XZ:ab

00522710-1031000